Takeda Pharmaceutical Co. Ltd. has entered into an exclusive partnership to develop and commercialize Contrave (naltrexone SR/bupropion SR), Orexigen‘s investigational drug for the treatment of obesity, in the U.S., Canada and Mexico. The two companies will work together on the development of the product, with Orexigen leading pre-approval activities, and Takeda leading post-approval activities. The parties will share development costs. Contrave is a combination therapy developed to add...